Edition:
United States

People: Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

3.50USD
18 Apr 2019
Change (% chg)

$-0.03 (-0.85%)
Prev Close
$3.53
Open
$3.52
Day's High
$3.57
Day's Low
$3.43
Volume
56,598
Avg. Vol
106,593
52-wk High
$7.16
52-wk Low
$3.31

Brinkley, David 

Mr. David L. Brinkley is an Independent Director of ARATANA THERAPEUTICS, INC. Mr. Brinkley worked for Theravance, Inc., a publicly-traded biopharmaceutical company, from 2000 to 2013, most recently as the Head of Business Development from November 2008 to July 2013. Mr. Brinkley had previously served as Senior Vice President, Commercial Development at Theravance from September 2000 through December 2007, when he left to start a consulting practice. From 1996 to 2000 he served as Worldwide Team Leader for Viagra at Pfizer Inc., leading the team that had full responsibility for the global launch and marketing of Viagra. Mr. Brinkley joined Pfizer in 1995 through its acquisition of SmithKline Beecham’s Animal Health operations and was director of new product planning before leading the Viagra launch team. Mr. Brinkley held various management positions with SmithKline Animal Health from 1983 to 1995. Mr. Brinkley previously served on the board of directors of Ziarco Pharma Ltd., a privately-held pharmaceutical company. Mr. Brinkley holds an M.A. with honors in International Economics from the School of Advanced International Studies of the Johns Hopkins University and a B.A. in International Relations from Kent State University, where he graduated with University Honors.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Awards, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --